Exosomes for targeting KRAS in the treatment of pancreatic cancer

被引：0
|
作者：
Louis Buscail
机构：
[1] Centre of Clinical Investigation for Biotherapy and INSERM U1037,Department of Gastroenterology
[2] Rangueil Hospital,undefined
[3] Centre Hospitalier Universitaire of Toulouse and University of Toulouse 3,undefined
来源：
Nature Reviews Gastroenterology & Hepatology | 2017年 / 14卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
KRAS oncogene mutations are commonly encountered in pancreatic ductal adenocarcinoma, driving tumour initiation, proliferation, progression and metastasis. Human exosomes engineered to deliver small interfering RNA silencing KRASG12D are highly efficient at specifically targeting pancreatic cancer cells to dramatically reduce RAS activation, cancer cell proliferation and metastatic processes.
引用
收藏
页码：636 / 638
页数：2
相关论文
共 50 条
  • [31] Combination inhibitor strategies targeting KRAS effector signaling in KRAS-mutant pancreatic cancer.
    Ozkan-Dagliyan, Irem
    Goodwin, Craig M.
    Bryant, Kirsten L.
    George, Samuel D.
    Lucas, Kelly
    Gautam, Prson
    Wennerberg, Krister
    Cox, Adrienne D.
    Der, Channing J.
    MOLECULAR CANCER RESEARCH, 2020, 18 (05) : 68 - 68
  • [32] Targeting EGFR in Pancreatic Cancer Treatment
    Troiani, T.
    Martinelli, E.
    Capasso, A.
    Morgillo, F.
    Orditura, Michele
    De Vita, F.
    Ciardiello, F.
    CURRENT DRUG TARGETS, 2012, 13 (06) : 802 - 810
  • [33] A CRISPR-Cas13a system for efficient and specific therapeutic targeting of mutant KRAS for pancreatic cancer treatment
    Zhao, Xiao
    Liu, Liang
    Liang, Jiayan
    Cheng, Keman
    Wang, Yongwei
    Li, Xueyan
    Shi, Jian
    Wang, Yanli
    Nie, Guangjun
    CANCER LETTERS, 2018, 431 : 171 - 181
  • [34] Targeting mutant p53 and KRAS for novel pancreatic cancer therapy by combination treatment of simvastatin and imipridones
    Tian, Xiaobing
    Deiry, Wafik S.
    CANCER RESEARCH, 2023, 83 (07)
  • [35] Targeting RABL3 to disrupt KRAS trafficking and activity in pancreatic cancer
    Jeong, Woo-Jeong
    Aney, Katherine J.
    Chen, Ethan
    Yang, Annan
    Uribe, Giselle A.
    Aguirre, Andrew
    Nissim, Sahar
    CANCER RESEARCH, 2024, 84 (02)
  • [36] Targeting KRAS in Pancreatic Cancer by Gene Silencing with U1 Adaptors
    Tsang, Ashley T.
    Yu, Xin
    Goraczniak, Rafal
    Brenneman, Mark
    Gunderson, Samuel
    Carpizo, Darren R.
    MOLECULAR THERAPY, 2015, 23 : S276 - S277
  • [37] Identification of T-cell receptors targeting mutant KRAS in pancreatic cancer
    Bear, Adham S.
    Rech, Andrew J.
    Richman, Lee P.
    O'Hara, Mark H.
    Linette, Gerald P.
    Carreno, Beatriz M.
    Vonderheide, Robert H.
    CANCER RESEARCH, 2019, 79 (24)
  • [38] Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer
    Buscail, Louis
    Bournet, Barbara
    Cordelier, Pierre
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2020, 17 (03) : 153 - 168
  • [39] KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment
    Zeitouni, Daniel
    Pylayeva-Gupta, Yuliya
    Der, Channing J.
    Bryant, Kirsten L.
    CANCERS, 2016, 8 (04)
  • [40] Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment
    Zhou, Wenxi
    Zhou, Yu
    Chen, Xinli
    Ning, Tingting
    Chen, Hongyi
    Guo, Qin
    Zhang, Yiwen
    Liu, Peixin
    Zhang, Yujie
    Li, Chao
    Chu, Yongchao
    Sun, Tao
    Jiang, Chen
    BIOMATERIALS, 2021, 268
12345